Zydus Lifesciences gets FDA approval for Ivermectin Cream, 1%

TAGS

Lifesciences (previously called Cadila Healthcare) has secured final approval for antiparasitic ointment Cream, 1% from the Food and Drug Administration (FDA).

Cream, 1% is the generic of Soolantra, which is used for treating inflammatory lesions of rosacea.

Lifesciences will manufacture Cream at its topical manufacturing facility in Ahmedabad, India.

Zydus Lifesciences gets FDA approval for Ivermectin Cream, 1%

Lifesciences gets FDA approval for Cream, 1%. Photo courtesy of Zydus Cadila.

As per IQVIA MAT June 2022, Cream had annual sales of 176 million in the US.

Lifesciences currently has 319 approvals and to date has filed more than 420 abbreviated new drug applications (ANDAs) since the start of the filing process in FY 2003-04.

CATEGORIES
TAGS
Share This

COMMENTS

Wordpress (0)
Disqus ( )